JRJoao Baptista Rezende-Neto

Joao Baptista Rezende-Neto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joao Baptista Rezende-Neto has a total of 160 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Noninvasive fascial traction improves primary fascial closure and reduces the incidence of incisional hernia in open abdomens

    by Tyee Kenneth Fellows, Deanna Ng, Ori Rotstein, Joao B. Rezende-Neto, Canada Toronto

    BACKGROUND: Open abdomens (OA) remain a major source of morbidity and mortality in trauma and emergency general surgery (EGS). Fascial traction has been shown to improve primary closure of the OA. However, reports on the incidence of incisional hernias (IH) after OA closure are scarce. The purpose of this study was to evaluate factors associated with primary fascial closure and the development of IH in OA managed with two different methods. METHODS: A retrospective cohort study of all OA patients with midline laparotomies for trauma and EGS (January 2019 to October 2024) in a level 1 trauma center. Patients were divided into two groups, those treated with a noninvasive fascial traction device in conjunction with negative pressure wound therapy (NPWT) system (AbClo + AbThera) and those treated only with NPWT system. Outcomes included fascial width at closure attempt, primary closure (fascia-to-fascia), and incidence of IH. Univariate regression models were performed to identify factors associated with IH. RESULTS: A total of 143 patients met inclusion criteria, 85 (59.4%) used AbClo + AbThera and 58 (40.6%) AbThera only. Primary closures were 94.1% (AbClo + AbThera) versus 72.4% (AbThera only); absolute risk difference 21.7% (95% CI: 9.5-34.8) and relative risk 1.30. Fascial widths were narrower in successful closures 6.0 versus 11.9 cm and in AbClo + AbThera (4.0 cm) versus AbThera alone (10.2 cm); 61.3% reduction in gap size; (all P P J Trauma Acute Care Surg . 2026;00: 000–000. Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Surgery of Trauma.) LEVEL OF EVIDENCE: Retrospective Comparative Study; Level IV.


  • Surgery-confirmed internal hernia with or without Roux-en-Y anastomosis: diagnostic performance of six CT signs

    by Hyun Kyung Yang, Joao Baptista Rezende-Neto, Viviane Willig Brasil, Errol Colak

    Purpose To assess the diagnostic performance and generalizability of established CT signs of internal hernias across a broad patient population including those with and without Roux-en Y anastomosis. Methods Our institutional review board approved this retrospective study. CT scans of 21 patients (11 women, 10 men) with surgically confirmed internal hernia and 52 control patients (23 women, 29 men) in whom internal hernia was suspected on CT but subsequently excluded surgically were reviewed. Six CT signs were evaluated: non-duodenal small bowel (ND-SB) behind the superior mesenteric artery (SMA), right-sided jejunojejunal anastomosis in applicable patients, “swirl” sign, superior mesenteric vein compression, “mushroom” sign, and clustered small bowel (SB) loops. Sensitivity, specificity, and odds ratios with 95% confidence intervals were calculated for each sign using logistic regression. Results Logistic regression identified the “mushroom” sign, clustered SB, and ND-SB behind the SMA as significant independent predictors of internal hernia with an area under the receiver operating characteristic curve of 0.746. The sensitivity, specificity, and odds ratio of the “mushroom” sign, clustered SB, and ND-SB behind the SMA were 38.1%, 86.5%, 3.96 (95% CI, 1.21–12.97), 47.6%, 75.0%, 2.73 (95% CI, 0.94–7.89), and 33.3%, 88.2%, 3.75 (95% CI, 1.08–13.02), respectively. Conclusion The “mushroom” sign, clustered SB, and ND-SB behind the SMA are valuable CT findings in diagnosing internal hernias irrespective of Roux-en-Y anastomosis. In particular, ND-SB behind the SMA and the “mushroom” sign are highly specific. Graphical Abstract

  • Management of Enteroatmospheric Fistulas: What you need to know

    by Joao B. MD Rezende-Neto, Charline RN Ductan, Brian PharmD Jurewitsch, Paulo R. Lima Carreiro, Natalia Causada Md Calo, Kareem Khalaf, Matthew Wu, Samar Abdullah Aljehani, Fernanda Y. Md Takamatsu

    An enteroatmospheric fistula (EAF) is a disastrous complication of abdominal surgery. Most EAFs occur in open abdomens after damage-control procedures in trauma and emergency general surgery. The absence of a defined fistulous tract and abdominal wall coverage preclude spontaneous closure and entail several challenges. Therefore, the primary objective is to manage those challenges to allow for the surgical take down of the fistulized bowel and reestablish gastrointestinal continuity. This work discusses a multidisciplinary approach indicating practical strategies from at least six different disciplines involved in the care of EAF patients.


  • Open Access

    Early placement of a non-invasive, pressure-regulated, fascial reapproximation device improves reduction of the fascial gap in open abdomens: a retrospective cohort study

    by Asad Naveed, Niels D Martin, Mohammed Bawazeer, Atif Jastaniah, Joao B Rezende-Neto

    Background: Since current fascial traction methods involve invasive procedures, they are generally employed late in the management of the open abdomen (OA). This study aimed to evaluate early versus late placement of a non-invasive, pressure-regulated device for fascial reapproximation and gap reduction in OA patients. Methods: The study included all patients who had the abdominal fascia intentionally left open after damage control operation for trauma and emergency general surgery and were managed with the device in an academic hospital between January 1, 2020, and December 31, 2023. Time of device placement in relation to the end of index laparotomy was defined as early (≤24 hours) versus late (>24 hours). Time-related mid-incisional width reduction of the fascial gap and fascial closure were assessed using descriptive and linear regression analysis. Results: There was a significantly higher percent reduction in the fascial gap at the midpoint of the laparotomies in the early (≤24 hours) AbClo placement group compared with the late (>24 hours) AbClo placement group, respectively, median 76% versus 43%, p<0.001. Linear regression adjusting for body mass index and the number of takebacks indicated that fascial approximation was 22% higher for early placement (β=0.22; CI 0.12, 0.33, p24 hours). Early non-invasive intervention could prevent abdominal wall myofascial retraction in OA patients. Level of evidence: IV.


  • Open Access

    Are Surgeons Going to Be Left Holding the Bag? Incisional Hernia Repair and Intra-Peritoneal Non-Absorbable Mesh Implant Complications

    by Andrew W. Kirkpatrick, Federico Coccolini, Matti Tolonen, Samual Minor, Fausto Catena, Andrea Celotti, Emanuel Gois, Gennaro Perrone, Giuseppe Novelli, Gianluca Garulli, et al.

    Ventral incisional hernias are common indications for elective repair and frequently complicated by recurrence. Surgical meshes, which may be synthetic, bio-synthetic, or biological, decrease recurrence and, resultingly, their use has become standard. While most patients are greatly benefited, mesh represents a permanently implanted foreign body. Mesh may be implanted within the intra-peritoneal, preperitoneal, retrorectus, inlay, or onlay anatomic positions. Meshes may be associated with complications that may be early or late and range from minor to severe. Long-term complications with intra-peritoneal synthetic mesh (IPSM) in apposition to the viscera are particularly at risk for adhesions and potential enteric fistula formation. The overall rate of such complications is difficult to appreciate due to poor long-term follow-up data, although it behooves surgeons to understand these risks as they are the ones who implant these devices. All surgeons need to be aware that meshes are commercial devices that are delivered into their operating room without scientific evidence of efficacy or even safety due to the unique regulatory practices that distinguish medical devices from medications. Thus, surgeons must continue to advocate for more stringent oversight and improved scientific evaluation to serve our patients properly and protect the patient–surgeon relationship as the only rationale long-term strategy to avoid ongoing complications.


  • Open Access

    Titratable partial aortic occlusion: Extending Zone I endovascular occlusion times

    by David Gomez, Asad Naveed, Joao Rezende, Bradley M. Dennis, Rishi Kundi, Elizabeth Benjamin, Ryan Lawless, Jonathan Nguyen, Juan Duchesne, Chance Spalding, et al.

    BACKGROUND: Extending the time to definitive hemorrhage control in noncompressible torso hemorrhage (NCTH) is of particular importance in the battlefield where transfer times are prolonged and NCTH remains the leading cause of death. While resuscitative endovascular balloon occlusion of the aorta is widely practiced as an initial adjunct for the management of NCTH, concerns for ischemic complications after 30 minutes of compete aortic occlusion deters many from zone 1 deployment. We hypothesize that extended zone 1 occlusion times will be enabled by novel purpose-built devices that allow for titratable partial aortic occlusion. METHODS: This is a cross-sectional analysis describing pREBOA-PRO zone 1 deployment characteristics at seven level 1 trauma centers in the United States and Canada (March 30, 2021, and June 30, 2022). To compare patterns of zone 1 aortic occlusion, the AORTA registry was used. Data were limited to adult patients who underwent successful occlusion in zone 1 (2013–2022). RESULTS: One hundred twenty-two patients pREBOA-PRO patients were included. Most catheters were deployed in zone 1 (n = 89 [73%]) with a median zone 1 total occlusion time of 40 minutes (interquartile range, 25–74). A sequence of complete followed by partial occlusion was used in 42% (n = 37) of zone 1 occlusion patients; a median of 76% (interquartile range, 60–87%) of total occlusion time was partial occlusion in this group. As was seen in the prospectively collected data, longer median total occlusion times were observed in the titratable occlusion group in AORTA compared with the complete occlusion group. CONCLUSION: Longer zone 1 aortic occlusion times seen with titratable aortic occlusion catheters appear to be driven by the feasibility of controlled partial occlusion. The ability to extend safe aortic occlusion times may have significant impact to combat casualty care where exsanguination from NCTH is the leading source of potentially preventable deaths. LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.


  • Open Access

    The unrestricted global effort to complete the COOL trial

    by Andrew W. Kirkpatrick, Federico Coccolini, Matti Tolonen, Samuel Minor, Fausto Catena, Emanuel Gois, Christopher J. Doig, Michael D. Hill, Luca Ansaloni, Massimo Chiarugi, et al.

    Background: Severe complicated intra-abdominal sepsis (SCIAS) has an increasing incidence with mortality rates over 80% in some settings. Mortality typically results from disruption of the gastrointestinal tract, progressive and self-perpetuating bio-mediator generation, systemic inflammation, and multiple organ failure. A further therapeutic option may be open abdomen (OA) management with negative peritoneal pressure therapy (NPPT) to remove inflammatory ascites and attenuate the systemic damage from SCIAS, although there are definite risks of leaving the abdomen open whenever it might possibly be closed. This potential therapeutic paradigm is the rationale being assessed in the Closed Or Open after Laparotomy (COOL trial) (https://clinicaltrials.gov/ct2/show/NCT03163095). Initially, the COOL trial received Industry sponsorship; however, this funding mandated the use of a specific trademarked and expensive NPPT device in half of the patients allocated to the intervention (open) arm. In August 2022, the 3 M/Acelity Corporation without consultation but within the terms of the contract canceled the financial support of the trial. Although creating financial difficulty, there is now no restriction on specific NPPT devices and removing a cost-prohibitive intervention creates an opportunity to expand the COOL trial to a truly global basis. This document describes the evolution of the COOL trial, with a focus on future opportunities for global growth of the study. Methods: The COOL trial is the largest prospective randomized controlled trial examining the random allocation of SCIAS patients intra-operatively to either formal closure of the fascia or the use of the OA with an application of an NPPT dressing. Patients are eligible if they have free uncontained intraperitoneal contamination and physiologic derangements exemplified by septic shock OR severely adverse predicted clinical outcomes. The primary outcome is intended to definitively inform global practice by conclusively evaluating 90-day survival. Initial recruitment has been lower than hoped but satisfactory, and the COOL steering committee and trial investigators intend with increased global support to continue enrollment until recruitment ensures a definitive answer. Discussion: OA is mandated in many cases of SCIAS such as the risk of abdominal compartment syndrome associated with closure, or a planned second look as for example part of “damage control”; however, improved source control (locally and systemically) is the most uncertain indication for an OA. The COOL trial seeks to expand potential sites and proceed with the evaluation of NPPT agnostic to device, to properly examine the hypothesis that this treatment attenuates systemic damage and improves survival. This approach will not affect internal validity and should improve the external validity of any observed results of the intervention. Trial registration: National Institutes of Health (https://clinicaltrials.gov/ct2/show/NCT03163095).


  • Perspectives on the management of non-compressible torso hemorrhage: A narrative review

    by Stephanie Leclerc, Sachin Doshi, Joao B. Rezende-Neto

    LAY SUMMARY Hemorrhage is one of the leading causes of death after trauma. A significant proportion of these fatalities could be prevented with appropriate bleeding control. This is more easily achieved with direct pressure in compressible areas such as the extremities or major joints. However, bleeding in the chest, abdomen, or pelvis cannot be as easily controlled without advanced procedures that are only available in hospitals. This article describes several technologies to control bleeding in the chest, abdomen, and pelvis that are potentially applicable in combat and pre-hospital settings. However, a review of existing studies quickly shows that convincing clinical evidence is lacking to support most pre-existing technologies, and the majority of studies are in the investigational stage. A universal, effective, and life-saving solution has not yet been identified. Accordingly, research in this area should continue to focus on both refining existing technologies and developing new approaches. More than 50% of combat casualty deaths on the battlefield occur minutes to hours after a person has been wounded. Approximately 25% of those fatalities could potentially be prevented if rapid hemorrhage control or temporization were feasible. Despite several technologies to temporize non-compressible torso hemorrhage (NCTH), an ideal device and method have not yet been developed, particularly for role 1 military medical treatment facilities and civilian pre-hospital settings. This article summarizes the devices and adjunct methods currently available to temporize NCTH when surgical and interventional radiology control are not readily accessible. New technologies under investigation are also discussed.


  • A novel inflatable device for perihepatic packing and hepatic hemorrhage control: A proof-of-concept study

    by Joao Rezende-Neto, Sachin Doshi, David Gomez, Bruna Camilotti, Dan Marcuzzi, Andrew Beckett